Patrick Heron Buys 131,425 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Patrick Heron purchased 131,425 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 23rd. The stock was acquired at an average cost of $68.48 per share, with a total value of $8,999,984.00. Following the acquisition, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mirum Pharmaceuticals Trading Up 2.4%

MIRM stock traded up $2.35 during trading on Tuesday, reaching $99.27. 679,931 shares of the stock were exchanged, compared to its average volume of 877,176. The firm has a market capitalization of $5.10 billion, a price-to-earnings ratio of -115.43 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $99.44. The business has a 50 day moving average price of $77.82 and a 200-day moving average price of $71.21.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter last year, the company earned ($0.30) earnings per share. The firm’s revenue was up 47.1% compared to the same quarter last year. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

MIRM has been the subject of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, JMP Securities set a $95.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.92.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
• Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long‑range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
• Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
• Positive Sentiment: Momentum / new 52‑week high after upgrades — The stock hit a fresh 52‑week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52‑Week High
• Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short‑term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. MCF Advisors LLC boosted its position in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $33,000. Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Quarry LP purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at about $41,000. Finally, CWM LLC lifted its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.